State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say researchers at Yale’s School of Public Health and School of Medicine. Their study was published in the American Journal of Public Health.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
